' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study).
Beheshti, M; Kunit, T; Haim, S; Zakavi, R; Schiller, C; Stephens, A; Dinkelborg, L; Langsteger, W; Loidl, W;
Mol Imaging Biol. 2015; 17(3):424-433
Originalarbeiten (Zeitschrift)

PMU-Autor/inn/en

Kunit Thomas

Abstract

PURPOSE
(2RS,4S)-2-[(18)F]Fluoro-4-phosphonomethyl-pentanedioic acid (BAY1075553) shows increased uptake in prostate cancer cells. We compared the diagnostic potential of positron emission tomography (PET)-X-ray computed tomography (CT) imaging using BAY1075553 versus [(18)F]f luorocholine (FCH) PET-CT.
Twelve prostate cancer patients (nine staging, three re-staging) were included. The mean prostate-specific antigen in the primary staging and re-staging groups was 21.5 ± 12 and 73.6 ± 33 ng/ml, respectively. Gleason score ranged from 5-9. In nine patients imaged for pre-operative staging, the median Gleason score was 8 (range, 7-9). PET acquisition started with dynamic PET images in the pelvic region followed by static whole-body acquisition. The patients were monitored for 5-8 days afterward for adverse events.
There were no relevant changes in laboratory values or physical examination. Urinary bladder wall received the largest dose equivalent 0.12 mSv/MBq. The whole-body mean effective dose was 0.015 mSv/MBq. There was a significant correlation between detected prostatic lesions by the two imaging modalities (Kappa = 0.356, P < 0.001) and no significant difference in sensitivity (P = 0.16) and specificity (P = 0.41). The sensitivity and specificity of PET imaging using BAY1075553 for lymph node (LN) staging was 42.9 % and 100 %, while it was 81.2 % and 50 % using FCH. The two modalities were closely correlated regarding detection of LNs and bone metastases, although BAY1075553 failed to detect a bone marrow metastasis. Degenerative bone lesions often displayed intense uptake of BAY1075553.
BAY1075553 PET-CT produced no adverse effects, was well tolerated, and detected primary and metastatic prostate cancer. FCH PET-CT results were superior, however, with respect to detecting LN and bone marrow metastases.


Useful keywords (using NLM MeSH Indexing)

Aged

Aged, 80 and over

Bone Marrow/pathology

Choline/analogs*

derivatives

Choline/chemistry

Fluorodeoxyglucose F18/chemistry

Glutarates/chemistry*

Humans

Lymphatic Metastasis/pathology

Male

Middle Aged

Neoplasm Metastasis

Neoplasm Recurrence, Local

Neoplasm Staging

Organophosphonates/chemistry*

Positron-Emission Tomography

Prospective Studies

Prostate-Specific Antigen/metabolism*

Prostatic Neoplasms/diagnostic imaging*

Radiometry

Sensitivity and Specificity

Tomography, X-Ray Computed


Find related publications in this database (Keywords)

BAY1075553
FCH
PET-CT
Prostate cancer
PSMA